Holen Sie sich die Stockscreener-App
0.5556
5.78%
0.0177
Schlusskurs vom Vortag:
$0.5379
Offen:
$0.5336
24-Stunden-Volumen:
295.08K
Relative Volume:
0.94
Marktkapitalisierung:
$11.00M
Einnahmen:
$420.00K
Nettoeinkommen (Verlust:
$-19.65M
KGV:
-0.00402
EPS:
-138.243
Netto-Cashflow:
$-26.08M
1W Leistung:
+8.90%
1M Leistung:
-23.91%
6M Leistung:
-95.63%
1J Leistung:
-99.92%
1-Tages-Spanne:
$0.529
$0.60
1-Wochen-Bereich:
$0.4901
$0.60
52-Wochen-Spanne:
$0.4901
$1,030.00
Kala Bio Inc Stock (KALA) Company Profile
Firmenname
Kala Bio Inc
Sektor
Branche
Telefon
781-996-5252
Adresse
1167 MASSACHUSETTS AVENUE, ARLINGTON, MA
Compare KALA vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KALA
Kala Bio Inc
|
0.5687 | 10.40M | 420.00K | -19.65M | -26.08M | -138.24 |
VRTX
Vertex Pharmaceuticals Inc
|
522.23 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
800.17 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,000.06 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.44 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.05 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kala Bio Inc Stock (KALA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-30 | Herabstufung | Mizuho | Outperform → Neutral |
| 2025-09-29 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-09-29 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2025-09-08 | Eingeleitet | Mizuho | Outperform |
| 2025-07-11 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2022-03-30 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2021-08-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-09-14 | Herabstufung | Jefferies | Buy → Hold |
| 2020-07-23 | Eingeleitet | Northland Capital | Outperform |
| 2020-06-01 | Fortgesetzt | Oppenheimer | Outperform |
| 2020-05-27 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-09 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-12-17 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-03-14 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Kala Bio Inc Aktie (KALA) Neueste Nachrichten
Kala Bio secures exclusive U.S. rights to Virotek genetic tests By Investing.com - Investing.com Nigeria
KALA Stock Update: Exclusive U.S. Distribution Deal with Virotek Highlights Growth Challenges - GuruFocus
Kala Bio Signs Exclusive U.S. Distribution Agreement for Virotek Ophthalmology Genetic Tests - Yahoo Finance
Kala Bio secures exclusive U.S. rights to Virotek genetic tests - Investing.com
For one year, eye-condition genetic tests will have one U.S. seller, Kala Bio. Virotek still processes samples. - Stock Titan
Kala Bio Targets Near-Term Revenue With Virotek Ophthalmology Genetic Testing Partnership - Yahoo Finance
Kala Bio, Virotek enters LOI for distribution agreement - TipRanks
KALA Bio (KALA) Signs Exclusive Distribution LOI with Virotek, F - GuruFocus
Kala Bio, Inc. and Virotek Inc. Announce Letter of Intent to Establish Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program - marketscreener.com
KALA BIO Faces Nasdaq Listing Compliance Uncertainty - The Globe and Mail
KALA BIO Faces Nasdaq Delisting Risk on Minimum Bid Price Failure - Minichart
KALA BIO Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
KALA (KALA) Close: Ends Down by 2.39% at $0.82 at the Close; Boundary Watch: Traders Can Monitor the $0.78-$0.86 Range in the Latest ReadingLow Vol ETF - vinanet.vn
KALA (KALA) Technicals: Moves 6.67% Down to $0.84; Technical Setup: the Supplied Trading Band Runs From $0.80 to $0.88 at the CloseProtective Put - vinanet.vn
KALA Stock Hits Record Low – Firm Announces Reverse Split After Shares Fail To Surpass The $1 Mark - Stocktwits
KALA BIO: Q2 Earnings Snapshot - AOL.com
KALA BIO Q2 Net Loss Narrows to $1.58 Million Amid Sharp Spending Cuts - Minichart
KALA BIO, Inc. Q2 2026: Net loss $(1.58M), EPS $(21.32) — 10-Q Summary - TradingView
KALA: Net loss narrowed sharply as focus shifted to AI platform, with liquidity supported by note receivable - TradingView
KALA BIO (KALA) pivots to biotech AI with $229K on hand - Stock Titan
KALA (KALA) Session: Retreats 0.97% to $0.89; Next Session: Price Remains Between $0.85 Support and $0.93 Resistance in the Latest ReadingRTH Profile - vinanet.vn
KALA Q4 2025 Earnings: Loss Narrows to -33.5 Per Share, Beating Estimates by 54.38Performance Review - vinanet.vn
KALA BIO Announces Brief Delay in Quarterly Filing - TipRanks
KALA BIO (KALA) delays June 30, 2026 Form 10-Q to finalize liquidity analysis - Stock Titan
KALA Q4 2025 Earnings: Narrower-Than-Expected Loss Delivers a 54.38 EPS SurpriseDividend Growth Analysis - vinanet.vn
KALA BIO Inc (KALA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
KALA BIO (KALA) Climbs 4.4% to $0.73 as Bulls Target $0.77 ResistanceSell Signal Alerts - dars.gov.et
KALA Q2'26 Earnings: EPS estimate is (6.00) USD - TradingView
KALA BIO Inc. (KALA) Gains 3.59% to $0.76 — Approaches Key Resistance at $0.80Institutional Buy Signals - vinanet.vn
KALA BIO Inc (KALA) Institutional Confidence - TradingKey
KALA Q2'26 Earnings: revenue estimate is 0 USD - TradingView
KALA BIO Inc (KALA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
KALA BIO Inc (KALA) Cash Flow - TradingKey
KALA BIO Inc (KALA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
KALA BIO Inc (KALA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
KALA Q4 2025 Earnings: Significant Beat on EPS Despite No Reported RevenueRevenue Inflection Point - vinanet.vn
TradingKey - TradingKey
KALA BIO Inc (KALA) Balance Sheet - TradingKey
KALA|KALA BIO Inc|Price:0.740|Chg%:-0.003 - TradingKey
KALA|KALA BIO Inc|Price:0.812|Chg%:-0.004 - TradingKey
KALA BIO, Inc. Revenue Breakdown – NASDAQ:KALA - TradingView
KALA|KALA BIO Inc|Price:0.634|Chg%:+0.024 - TradingKey
KALA BIO Inc (KALA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Kala Bio, Inc. Files Form 8-K with SEC Detailing Nasdaq Listing and Corporate Information - Minichart
KALA Bio (KALA) Slides 13% as Sellers Test Critical Floor Near $0.61Volatility Smile - vinanet.vn
Kala Bio Files ATM Offering Of Up To $250 Million In Common StockSEC Filing - TradingView
Frontier tech research, news & data - MLQ.ai
KALA BIO Shares Plunge Over 7% as Stock Nears Critical Support LevelGamma Flip Level - vinanet.vn
Kala Bio announces 1-for-50 reverse stock split effective Friday - Investing.com
Form 13D/A KALA BIO For: 2 July By Investing.com - Investing.com Nigeria
David Lazar trims KALA BIO (KALA) stake to 3.9% with 719,404 shares - Stock Titan
Finanzdaten der Kala Bio Inc-Aktie (KALA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.72%
1.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):